

1 **Appendix**

2
3 **Rapid metagenomic DNA sequencing to diagnose bloodstream infections in patients**
4 **admitted to the emergency ward**
5 **Nielsen et al.**
6

7 **Table of contents**

8 Supplementary Methods2
9 Potential clinical impact analysis2
10 Statistical analysis2
11 Supplementary Figures3
12 Figure S1. Clinical characteristics of patients who were analyzed and excluded.3
13 Figure S2. Clinical characteristics for patients in BSI-suspected with negative and positive mNGS results.4
14 Supplementary Tables5
15 Table S1. Detailed metadata on clinical presentation for all patients.5
16 Table S2. Detailed metadata on the assessment of relevance of mNGS findings.8
17 Table S3. Read depth and plasma cfDNA concentration for all patients and blood donors.11
18 References13

19
20

21 **Supplementary Methods**

22 **Potential clinical impact analysis**


23 Patient courses were evaluated for 3 different potential impact types. Firstly, a change from ineffective to effective
24 antibiotic treatment, when DNA sequencing results could have led to a correction from ineffective (either due to
25 antibiotic resistance or the antibiotic not covering the pathogen) to effective antibiotic treatment. This was adjudicated
26 only when the first-line antibiotic against the pathogen identified by DNA sequencing would have been effective.
27 Secondly, an addition of an extra antibiotic for coverage, when DNA sequencing results could have led to the addition
28 of one or more extra antibiotics to cover all identified pathogens relevant to the acute infection. Thirdly, extended
29 treatment, when the finding of a pathogen in the blood with DNA sequencing, that was already covered by the
30 antibiotic treatment could have led doctors to consider prolonging IV antibiotic treatment and admission. Only the
31 pathogens from mNGS adjudicated by the clinical microbiologists as relevant were considered in the impact analysis.
32 In the assessment of impact all of a patient's positive clinical microbiology diagnostics were considered, and e.g. a
33 change to effective treatment was only adjudicated if no relevant diagnostic answers were available at the time (6
34 hours post admission) to guide the treatment. Negative mNGS answers were not assessed for potential in guiding
35 deescalations.

36 **Statistical analysis**

37 The comparison of mNGS results to gold-standard blood culturing was conducted as follows: a true positive was
38 adjudicated when at least one pathogen identified by mNGS was in accordance with blood culturing; a true negative
39 was adjudicated when no pathogens were identified by neither blood culture or mNGS; a false positive was adjudicated
40 when blood culture was negative and mNGS was positive; a false negative was adjudicated when blood culture was
41 positive and mNGS was negative for that pathogen.²

42
43 If not specified otherwise, a two-sided Wilcoxon-Mann-Whitney test was used to compare distributions. In case of
44 multiple comparisons, the p-values were adjusted with the Holm-Bonferoni method. All statistical analyses were
45 conducted in R (version 4.2.0).



46 **Supplementary Figures**



47

48 **Figure S1. Clinical characteristics of patients who were analyzed and excluded.**

49 a) CRP at blood culture for BSI-confirmed, BSI-suspected, BSI-absent, and BSI-unlikely groups. b) qSOFA score at
 50 blood culture for the four groups. c) Systolic blood pressure at blood culture for the four groups. d) Temperature at
 51 blood culture for the four groups.



52

53 **Figure S2. Clinical characteristics for patients in BSI-suspected with negative and positive mNGS results.**

54 a) CRP at blood culture. b) Systolic blood pressure at blood culture.

55 **Supplementary Tables**56 **Table S1. Detailed metadata on clinical presentation and antibiotics for all patients.**

57

Patient	Suspected primary infection site	CRP (mg/L)	Systolic blood pressure (mmHg)	Temperature (°C)	WBC (10 ³ cells/mm ³)	RF (1/min)	GCS	qSOFA	Antibiotics prior to admission	Antibiotics during admission
p001	LRI	109	124	40.1	10.3	30	13	2		Gentamicine Cefuroxime Benzylpenicillin Ampicillin Piperacillin/tazobactam
p002	UTI	216	90	36.6	10.7	24	14	3		Gentamicin Piperacillin/tazobactam Meropenem Ciprofloxacin Ampicillin
p020	UTI	161	115	36.4	14.8	20	15	0		Piperacillin/tazobactam Mecillinam Pivmecillinam
p028	LRI	255	105	37.1	24.8	24	15	1		Amoxicillin Piperacillin/tazobactam
p098	Idiopathic pancreatitis	73	144	37.3	14.5	16	15	0		Piperacillin/tazobactam Metronidazole
p104	Infection w.o. focus	41	123	36.5	7.5	16	15	0		Piperacillin/tazobactam Ciprofloxacin Vancomycin
p139	Infection w.o. focus	248	129	37.4	5.3	18	15	0		Piperacillin/tazobactam Ciprofloxacin
p141	Knee	324	144	37.2	5.3	12	15	0		Cloxacillin Dicloxacillin Benzylpenicillin Cefuroxime
p172	UTI	245	107	40.3	17.1	16	15	0		Gentamicin Ampicillin Piperacillin/tazobactam Pivmecillinam Phenoxymethylpenicillin
p175	Infection w.o. focus	124	92	38.1	13.6	19	15	1		Piperacillin/tazobactam Vancomycin
p183	UTI	372	126	37.1	19.4	18	15	0		Piperacillin/tazobactam Ampicillin Metronidazole
p012	Infection w.o. focus	204	86	36.8	7.6	23	15	2	Metronidazole	Nystatin Amoxicillin Piperacillin/tazobactam
p018	PICC-line infection	37	95	36.9	4.8	12	15	1		Benzylpenicillin Fluconazole Ampicillin Anidulafungin
p019	LRI	284	103	38	10.8	22	15	1		Ampicillin Gentamicin Piperacillin/tazobactam
p022	Infection w.o. focus	175	101	35.1	18.1	16	15	0	Phenoxymethylpenicillin	Ampicillin Piperacillin/tazobactam Moxifloxacin

p027	Skin	63	99	37.3	10.9	18	15	1		Fluconazole Clarithromycin Piperacillin/tazobactam Dicloxacillin
p047	LRI	124	130	39.2	23.3	22	15	1		Benzylpenicillin Piperacillin/tazobactam Amoxicillin
p049	LRI	420	131	37.3	27.7	16	15	0		Cefuroxime Clarithromycin Roxithromycin Moxifloxacin
p072	UTI	207	144	37	15.5	16	15	0	Pivmecillinam	Ampicillin Pivampicillin Pivmecillinam Gentamicin
p091	UTI	261	108	37.2	12.3	14	15	0		Piperacillin/tazobactam Pivmecillinam
p092	UTI	212	108	37	10	14	15	0		Piperacillin/tazobactam Pivmecillinam
p105	LRI	233	137	38.7	23.4	22	15	1	Azithromycin	Clarithromycin Benzylpenicillin Piperacillin/tazobactam Amoxicillin Moxifloxacin
p106	LRI	387	117	37	13.1	22	15	1	Unknown antibiotic	Piperacillin/tazobactam Phenoxyethylpenicillin
p114	LRI	69	97	37.2	12.3	22	15	2		Benzylpenicillin Amoxicillin
p127	Diverticulitis	183	99	37.1	16.3	22	15	2		Metronidazole Benzylpenicillin Gentamicin Amoxicillin
p128	LRI	470	99	36.9	12.2	20	15	1		Benzylpenicillin Phenoxyethylpenicillin
p136	Psoas	303	105	37.8	15.4	12	15	0	Unknown antibiotic	Metronidazole Piperacillin/tazobactam Fluconazole
p140	UTI	81	132	38	13.6	16	15	0	Pivmecillinam	Ampicillin Gentamicin Pivmecillinam
p143	Decubitus os sacrum	231	110	37.8	14.1	18	14	1		Cefuroxime Amoxicillin
p146	Skin	65	104	36.9	10.5	18	15	0		Benzylpenicillin Cloxacillin Phenoxyethylpenicillin
p150	LRI	31	109	39.5	1.4	18	15	0		Ciprofloxacin Piperacillin/tazobactam Gentamicin Meropenem
p151	Infection w.o. focus	304	123	38.1	13	16	15	0		Cefuroxime Trimethoprim
p156	LRI	47	79	37.4	28.9	20	15	1		Piperacillin/tazobactam Amoxicillin
p162	LRI	32	98	37.3	9.4	28	15	2		Meropenem Ciprofloxacin

p164	UTI	234	119	38.3	7.3	14	15	0	Piperacillin/tazobactam Ciprofloxacin
p173	UTI	164	132	38	10	14	15	0	Vancomycin Pivmecillinam Ciprofloxacin
p016		119	152	36.5	9.8	14	15	0	
p059		1.2	155	36.4	6.4	20	15	0	
p068		1.3	150	36.5	10.1	16	15	0	
p120		1.3	137	37	9.6	16	15	0	Dicloxacillin

58 Abbreviations: RF = Respiratory frequency, WBC = White blood cell count, CRP = C-reactive protein, qSOFA =
59 Quick Sequential Organ Failure Assessment,³ GCS = Glasgow Coma Scale.

60 **Table S2. Detailed metadata on the assessment of relevance of mNGS findings.**

Patient	Blood culture result	Secondary microbiology result	mNGS result (GPM)	Clinical relevance of mNGS result	Potential impact on antibiotic treatment	Comments related to treatment impact
p001	<i>Enterococcus faecalis</i>	Urine: <i>E. faecalis</i>	<i>E. faecalis</i> (1)	Confirmed	Change	From gentamicin and cefuroxime to ampicillin
p002	<i>Escherichia coli</i>	Urine: <i>E. coli</i> , Urine: <i>Enterococcus</i> spp.	<i>E. coli</i> (20·8)	Confirmed	None	
p020	<i>E. coli</i>	Urine: <i>E. coli</i>	<i>E. coli</i> (1·6)	Confirmed	None	
p028	<i>E. coli</i>	Urine: <i>E. coli</i>	<i>E. coli</i> (41·3)	Confirmed	None	
p098	<i>E. coli</i>		<i>E. coli</i> (0·9)	Confirmed	None	
p104	<i>Staphylococcus epidermidis</i>		<i>S. epidermidis</i> (52·4) KSHV (1)	Confirmed	Change	From piperacillin/tazobactam to vancomycin
p139	<i>E. coli</i>		<i>E. coli</i> (102·2) <i>Enterococcus faecium</i> (0·7) CMV (26·6)	Confirmed	Addition	Addition of antiviral treatment
p141	<i>Staphylococcus aureus</i>	Urine: <i>S. aureus</i> , Joint: <i>S. aureus</i>	<i>S. aureus</i> (31)	Confirmed	Change	Patient was discharged without any antibiotic treatment and readmitted and started cloxacillin the next day when the blood culture was positive.
p172	<i>E. coli</i>	Urine: <i>E. coli</i>	<i>E. coli</i> (59·4)	Confirmed	None	
p175	<i>S. epidermidis</i>	Urine: <i>Enterococcus</i> spp.	<i>S. epidermidis</i> (53·8)	Confirmed	Change	From piperacillin/tazobactam to vancomycin
p183	<i>E. coli</i>	Urine: <i>E. coli</i> , Feces: <i>Clostridiodes difficile</i>	<i>E. coli</i> (320·8) <i>Citrobacter koseri</i> (2·4)	Confirmed	None	

p019			<i>E. coli</i> (58·7) <i>Haemophilus influenzae</i> (13·4) <i>Rothia dentocariosa</i> (4·5) <i>Streptococcus anginosus</i> (4·6) <i>Veillonella atypica</i> (6·5)	Probable	None	
p049			<i>Proteus mirabilis</i> (0·5)	Possible ^a	None	
p072			<i>E. coli</i> (2·8)	Probable	Escalation	Extended duration of IV antibiotic treatment
p091		Urine: <i>E. coli</i>	<i>E. coli</i> (1·8)	Probable	Escalation	Extended duration of IV antibiotic treatment
p092		Urine: <i>E. coli</i>	<i>E. coli</i> (0·9) <i>H. pylori</i> (13·8)	Probable	None	
p105		BAL: <i>Pseudomonas aeruginosa</i>	<i>P. aeruginosa</i> (121·6)	Probable	Change	From penicillin and clarithromycin to piperacillin/tazobactam and ciprofloxacin
p127			<i>Raoultella planticola</i> (0·6)	Probable	Escalation	Peroral escalation from amoxicillin to ciprofloxacin
p128			<i>S. pneumoniae</i> (3·5)	Probable	Escalation	Extended duration of IV antibiotic treatment
p140		Urine: <i>E. coli</i>	<i>E. coli</i> (5·9)	Probable	Escalation	Extended duration of IV antibiotic treatment
p143		Urine: <i>Enterococcus spp.</i> , Wound: <i>Proteus spp.</i>	<i>C. difficile</i> (0·5)	Unlikely	None	
p164		Urine: <i>E. coli</i>	<i>E. coli</i> (8)	Probable	Escalation	Extended duration of IV antibiotic treatment
p173		Urine: <i>Enterococcus spp.</i>	<i>Klebsiella spp.</i> (5·8) <i>Acinetobacter bereziniae</i> (1) <i>Brevibacterium paucivorans</i> (2) <i>Leuconostoc pseudomesenteroides</i> (1·1)	Probable	Escalation	Extended duration of IV antibiotic treatment

			<i>Pantoea dispersa</i> (1·1) <i>Serratia spp.</i> (3·1)			
--	--	--	-------------------------------------------------------------	--	--	--

61 Abbreviations: GPM = Genome Equivalents per microliter, KSHV = Kaposi's sarcoma-associated herpesvirus, CMV
62 = Cytomegalovirus, BAL = bronchoalveolar lavage
63 *Consistent with a bronchial lavage culture from a previous hospital admission, which supports the finding of *P.*
64 *mirabilis* in a patient with LRI focus.

65 **Table S3. Read depth and plasma cfDNA concentration for all patients and blood donors.**

Patient	DNA concentration (ng/mL)	Read depth (M)
p001	9.6	2.69
p002	3.6	2.1
p012	14.3	14.2
p016	3.8	5.72
p018	9.0	5.22
p019	70.9	10.2
p020	14.7	1.15
p022	4.1	8.11
p027	13.1	18.7
p028	27.0	9.15
p047	24.6	21.4
p049	19.2	5.94
p059	3.6	9.94
p068	2.7	0.629
p072	19.1	7.18
p091	8.4	10.3
p092	8.5	5.44
p098	7.4	9.99
p104	2.4	16.9
p105	21.6	5.61
p106	26.9	6.48
p114	6.0	18.2
p120	0.6	1.67
p127	2.8	11.8
p128	34.8	17.3
p136	16.6	18.3
p139	10.1	9.4

p140	10.0	16.6
p141	35.1	5.65
p143	19.2	11.3
p146	2.3	11.7
p150	152.1	6.3
p151	16.3	11.6
p156	10.9	4.22
p162	8.3	12.7
p164	21.6	12.6
p172	13.0	15.5
p173	13.7	10.4
p175	9.1	21
p183	136.8	10.5
d001	4.3	6.47
d002	4.5	10.3
d003	2.1	8.57
d004	1.3	10.4
d005	1.1	5.48
d006	2.4	13.6
d007	1.4	3.24
d008	0.8	14.5
d009	7.5	11.6
d010	2.3	16.7
d011	4.2	17.6
d012	2.7	2

66
67

68 **References**

- 69 1. Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, et al. Analytical and clinical validation of
70 a microbial cell-free DNA sequencing test for infectious disease. *Nat Microbiol.* 2019 Apr;4(4):663–74.
- 71 2. Feng S, Rao G, Wei X, Fu R, Hou M, Song Y, et al. Clinical metagenomic sequencing of plasma microbial cell-
72 free DNA for febrile neutropenia in patients with acute leukaemia. *Clin Microbiol Infect.* 2024 Jan;30(1):107–
73 13.
- 74 3. Lambden S, Laterre PF, Levy MM, Francois B. The SOFA score-development, utility and challenges of accurate
75 assessment in clinical trials. *Crit Care.* 2019 Nov 27;23(1):374.